Table 3. Factors associated with the use of biomarker testing in advanced CRC patients in China.
| Variables | Had biomarker testing (n=2,092), n (%) | Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | AOR (95% CI) | P value | |||
| Treating hospital | ||||||
| Cancer hospitals | 1,190 (57.2) | Ref | Ref | |||
| General hospitals | 902 (36.9) | 0.44 (0.38–0.49) | <0.001 | 0.39 (0.34–0.46) | <0.001 | |
| Age at survey day | ||||||
| <50 years | 426 (56.9) | Ref | – | |||
| ≥50 years | 1,666 (44.1) | 0.60 (0.51–0.70) | <0.001 | – | – | |
| Age at diagnosis | ||||||
| <50 years | 520 (56.5) | Ref | Ref | |||
| ≥50 years | 1,572 (43.6) | 0.60 (0.51–0.68) | <0.001 | 0.80 (0.66–0.97) | 0.026 | |
| Geographic† | ||||||
| Less developed areas | 955 (47.4) | Ref | – | |||
| Developed areas | 1,137 (45.2) | 0.92 (0.81–1.02) | 0.141 | – | – | |
| Gender | ||||||
| Males | 1,253 (46.5) | Ref | – | |||
| Females | 839 (45.8) | 0.97 (0.86–1.09) | 0.617 | – | – | |
| Educational level | ||||||
| ≤6 years | 471 (35.9) | Ref | Ref | |||
| 6–12 years | 1,175 (47.2) | 1.59 (1.38–1.82) | <0.001 | 1.30 (1.08–1.56) | 0.005 | |
| >12 years | 445 (61.8) | 2.89 (2.39–3.48) | <0.001 | 2.12 (1.61–2.80) | <0.001 | |
| Family income per year | ||||||
| <50,000 CNY | 1,125 (43.3) | Ref | Ref | |||
| 50,000–99,999 CNY | 583 (45.6) | 1.10 (0.96–1.25) | 0.163 | 0.99 (0.82–1.18) | 0.872 | |
| ≥100,000 CNY | 384 (59.4) | 1.92 (1.60–2.28) | <0.001 | 1.52 (1.19–1.94) | 0.001 | |
| Doctor recommend | ||||||
| No | 107 (7.3) | Ref | Ref | |||
| Yes | 1,982 (64.8) | 23.22 (18.80–28.60) | <0.001 | 23.61 (18.78–29.70) | <0.001 | |
| Tumor sites | ||||||
| Colon | 1,068 (51.9) | Ref | Ref | |||
| Rectal | 1,024 (41.5) | 0.66 (0.58–0.74) | <0.001 | 0.79 (0.67–0.92) | 0.003 | |
| Surgery | ||||||
| No | 399 (54.2) | Ref | – | |||
| Yes | 1,692 (44.7) | 0.68 (0.58–0.80) | <0.001 | – | – | |
| Adjuvant chemotherapy | ||||||
| No | 161 (26.5) | Ref | Ref | |||
| Yes | 1,930 (49.4) | 2.71 (2.23–3.27) | <0.001 | 1.54 (1.21–1.96) | 0.001 | |
| Adjuvant radiotherapy | ||||||
| No | 1,676 (47.7) | Ref | Ref | |||
| Yes | 415 (41.5) | 0.78 (0.67–0.80) | <0.001 | 0.78 (0.64–0.94) | 0.009 | |
| Stage at diagnosis | ||||||
| I & II | 291 (33.5) | Ref | – | |||
| III & IV | 1,737 (49.9) | 1.98 (1.69–2.31) | <0.001 | – | – | |
| Metastases | ||||||
| No | 1,016 (36.1) | Ref | Ref | |||
| Yes | 1,066 (63.0) | 3.01 (2.65–3.41) | <0.001 | 2.13 (1.82–2.49) | <0.001 | |
†, less developed areas: Central, Northwest, Southwest, and Northeast; developed areas: East, South, Northern. CRC, colorectal cancer; OR, odds ratio; AOR, adjusted odds ratio; CI, confidence interval; CNY, Chinese yuan.